Jerome Powell speaking at Jackson Hole, signals a September rate cut
SAN FRANCISCO - Novo Nordisk, a global healthcare company, and Hims & Hers Health, Inc. (NYSE: HIMS), a telehealth company, have announced a collaboration to enhance obesity care by making treatments more accessible and affordable for Americans. The partnership introduces a bundled offering of Novo Nordisk’s Wegovy® on the Hims & Hers platform, combining pharmaceutical therapy with comprehensive health services.
As part of the collaboration, Wegovy®, an FDA-approved medication for chronic weight management, will be available through the Hims & Hers platform. The service includes all dose strengths of Wegovy® and a Hims & Hers membership, which offers 24/7 care, clinical support, and nutrition guidance. The monthly subscription starts at $599 and is available starting this week.
The companies aim to improve long-term outcomes for individuals living with obesity by leveraging Novo Nordisk’s expertise in clinical medicine and Hims & Hers’ scalable approach to healthcare delivery. Andrew Dudum, CEO of Hims & Hers, expressed enthusiasm for the partnership and its potential to redefine consumer-centered healthcare.
Dave Moore, Executive Vice President at Novo Nordisk, highlighted the goal of providing improved care for chronic diseases more affordably. The collaboration is expected to build on Hims & Hers’ existing weight loss solutions, offering a comprehensive approach to health and wellness.
Hims & Hers Health, Inc. is recognized for its mission to promote better health and wellness. The company’s platform aims to personalize care and make health solutions more accessible.
The announcement of this collaboration is based on a press release statement from the companies involved.
In other recent news, Hims & Hers Health, Inc. reported developments affecting its financial outlook and operations. Citi analyst Daniel Grosslight revised the company’s stock price target to $25 from $27, maintaining a Sell rating. Grosslight anticipates that while Hims & Hers may exceed earnings estimates due to strong GLP-1 product performance, a slowdown in core revenue growth might overshadow these results. The potential risks include a weakening consumer environment and new pharmaceutical tariffs. Concurrently, BofA Securities maintained an Underperform rating on the company with a $22 price target, citing a deceleration in year-over-year sales growth. Despite this, first-quarter online revenue projections are positive, exceeding the Visible Alpha consensus. Additionally, Hims & Hers received a warning from the FDA regarding its compounded topical finasteride products, raising concerns about future regulatory actions. Finally, the company announced that COO Melissa Baird would transition to an advisory role, with a search underway for her successor.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.